Compare Alibaba Group (BABA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Twist Bioscience Corp — how do they compare? Alibaba Group trades at $124.56 (market cap $308.93B), while Twist Bioscience Corp trades at $123.24 (market cap $7.72B). The key difference: Alibaba Group is far larger — about 40× Twist Bioscience Corp's market cap, and Alibaba Group pays a 0.82% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BABA | TWST | |
|---|---|---|
Market Cap | $308.93B | $7.72B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $124.88 |
52-Week Low | $94.83 | $24.16 |
Enterprise Value | $303.72B | $7.65B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BABA trades at $132.32, up 3.04% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong 2025 results with $996.35B revenue and $130.11B net income, though recent quarterly EPS misses raise concerns. Analyst consensus remains strongly bullish with an $195.00 price target, but multiple class action lawsuits filed in August 2026 create significant legal overhang.
BABA presents a mixed investment case with strong fundamentals and Wall Street support offset by legal risks and earnings volatility. The stock trades at reasonable valuations (P/E 19.61, P/S 2.03) with solid profitability metrics, but investors must weigh the substantial legal challenges against the company's operational strength and growth trajectory.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
